These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 34221699)
1. Correction: Can Plasma α-Synuclein Help Us to Differentiate Parkinson's Disease from Essential Tremor? Albillos SM; Montero O; Calvo S; Solano B; Trejo JM; Cubo E Tremor Other Hyperkinet Mov (N Y); 2021 Jun; 11():24. PubMed ID: 34221699 [TBL] [Abstract][Full Text] [Related]
2. Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease. Si X; Tian J; Chen Y; Yan Y; Pu J; Zhang B Neuroscience; 2019 Aug; 413():308-316. PubMed ID: 31102760 [TBL] [Abstract][Full Text] [Related]
3. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. Papapetropoulos S; Paschalis C; Athanassiadou A; Papadimitriou A; Ellul J; Polymeropoulos MH; Papapetropoulos T J Neurol Neurosurg Psychiatry; 2001 May; 70(5):662-5. PubMed ID: 11309462 [TBL] [Abstract][Full Text] [Related]
5. Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Zange L; Noack C; Hahn K; Stenzel W; Lipp A Brain; 2015 Aug; 138(Pt 8):2310-21. PubMed ID: 26017579 [TBL] [Abstract][Full Text] [Related]
6. Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease. Chang CW; Yang SY; Yang CC; Chang CW; Wu YR Front Neurol; 2019; 10():1388. PubMed ID: 32038461 [No Abstract] [Full Text] [Related]
7. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies. Llorens F; Schmitz M; Varges D; Kruse N; Gotzmann N; Gmitterová K; Mollenhauer B; Zerr I J Neurol; 2016 Nov; 263(11):2271-2277. PubMed ID: 27544498 [TBL] [Abstract][Full Text] [Related]
8. EMG signal morphology and kinematic parameters in essential tremor and Parkinson's disease patients. Ruonala V; Meigal A; Rissanen SM; Airaksinen O; Kankaanpää M; Karjalainen PA J Electromyogr Kinesiol; 2014 Apr; 24(2):300-6. PubMed ID: 24462391 [TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease biomarkers based on α-synuclein. Fayyad M; Salim S; Majbour N; Erskine D; Stoops E; Mollenhauer B; El-Agnaf OMA J Neurochem; 2019 Sep; 150(5):626-636. PubMed ID: 31265130 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. Kalia LV Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800 [TBL] [Abstract][Full Text] [Related]
11. Features in essential tremor and the development of Parkinson's disease vs. parkinsonism. Lau HL; Marmol SE; Margolesky J Neurol Sci; 2020 Nov; 41(11):3249-3253. PubMed ID: 32394273 [TBL] [Abstract][Full Text] [Related]
13. Investigation of α-Synuclein Species in Plasma Exosomes and the Oligomeric and Phosphorylated α-Synuclein as Potential Peripheral Biomarker of Parkinson's Disease. Zheng H; Xie Z; Zhang X; Mao J; Wang M; Wei S; Fu Y; Zheng H; He Y; Chen H; Xu Y Neuroscience; 2021 Aug; 469():79-90. PubMed ID: 34186110 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448 [TBL] [Abstract][Full Text] [Related]
15. Plasma α-synuclein predicts cognitive decline in Parkinson's disease. Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072 [TBL] [Abstract][Full Text] [Related]
16. Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson's disease: A meta-analysis. Shafieesabet A; Fereshtehnejad SM; Shafieesabet A; Delbari A; Baradaran HR; Postuma RB; Lökk J Parkinsonism Relat Disord; 2017 Sep; 42():1-11. PubMed ID: 28647434 [TBL] [Abstract][Full Text] [Related]
17. Retinal α-synuclein deposits in Parkinson's disease patients and animal models. Veys L; Vandenabeele M; Ortuño-Lizarán I; Baekelandt V; Cuenca N; Moons L; De Groef L Acta Neuropathol; 2019 Mar; 137(3):379-395. PubMed ID: 30721408 [TBL] [Abstract][Full Text] [Related]
18. α-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson's disease. Mazzetti S; Basellini MJ; Ferri V; Cassani E; Cereda E; Paolini M; Calogero AM; Bolliri C; De Leonardis M; Sacilotto G; Cilia R; Cappelletti G; Pezzoli G Brain; 2020 Mar; 143(3):920-931. PubMed ID: 32025699 [TBL] [Abstract][Full Text] [Related]
19. Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control. Lin WC; Lu CH; Chiu PY; Yang SY Dement Geriatr Cogn Disord; 2020; 49(4):401-409. PubMed ID: 33242863 [TBL] [Abstract][Full Text] [Related]
20. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Shannon KM; Keshavarzian A; Dodiya HB; Jakate S; Kordower JH Mov Disord; 2012 May; 27(6):716-9. PubMed ID: 22550057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]